See other companies on Welcome to the Jungle
e-therapeutics
Computational drug discovery
- 21-100 employees
- Healthcare
- B2B
- Biology
- SaaS
- Science
- MedTech
- London, UK
Jump to section
Company mission
To compute the future of medicine.
Few candidates hear
back within 2 weeks
Our take
Novel drug discovery is a painfully slow operation, meaning that patients wait years for life-changing medication. This is what e-therapeutics wants to change, with its computational drug discovery platform that supports the faster discovery of RNAi medicines (an innovative new class of medicines).
The platform is a combination of two platforms, HepNet and GalOmic - the former being the computational side and the latter being a chemistry platform. Together, they generate a pipeline of life-transforming RNAi medicines with targets such as haemophilia, cardiometabolic disease and heart failure.
In 2024, after delisting from the London Stock Exchange, e-therapeutics has gone on to raise a substantial funding round. This will support the company's operations as it prepares for future endeavours such as a possible listing on NASDAQ.
Kirsty
Company Specialist at Welcome to the Jungle
Company values
- Passion & purpose
- Action & agility
- Courage & curiosity
- Teamwork
Funding (1 round)
Mar 2007
$0.6m
GRANT
Total funding: $0.6m
This company has top investors
Leadership
Ali Mortazavi
(CEO, not founder)Previously CEO at Silence Therapeutics for 6 years.